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Abstract
Introduction: Paliperidone, the 9-hydroxy metabolite of risperidone, is a second-generation antipsychotic that was recently approved
for the treatment of schizophrenia. It is marketed as an improvement over risperidone, but is likely to be considerably more costly when
risperidone is no longer protected by patent.
Aims: To review the evidence for the clinical impact of paliperidone in the treatment of patients with schizophrenia, particularly in contrast
to risperidone.
Evidence review: Paliperidone is primarily metabolized and excreted renally, and thus may be of particular utility for patients with
hepatic impairment. There is clear evidence that paliperidone is more efficacious than placebo in reducing the positive and negative
symptoms of schizophrenia. In patients with schizophrenia, paliperidone has been shown to stabilize acute psychotic symptoms. There
is some evidence that it can prevent relapse in stabilized patients. Studies on the cost effectiveness of paliperidone are needed. Most
importantly, there are no trials comparing paliperidone directly with other second-generation antipsychotics.
Place in therapy: Until direct efficacy and cost effectiveness comparisons are made with risperidone, it is difficult to justify paliperidone
use over risperidone. It will become even harder to justify when risperidone becomes available as a less expensive generic medication.
Core Evidence. 2008;2(4):261–271
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Core evidence place in therapy summary for paliperidone in schizophrenia
Outcome measure Evidence Implications
Patient-oriented outcomes
Reduction in positive and negative symptoms of
schizophrenia
Clear Clearly improves symptoms compared with placebo; comparisons with other
second-generation antipsychotics needed
Reduction in mood symptoms of schizophrenia Moderate Improves mood based on PANSS factor scores. More specific measures of
mood needed
Prevention of relapse in stabilized patients Moderate May be useful, although more robust evidence required
Adherence with treatment Clear Fewer patients may discontinue treatment; comparisons with other second-
generation antipsychotics needed
Extrapyramidal symptoms Clear Fewer extrapyramidal symptoms than first-generation antipsychotics, similar to
other second-generation antipsychotics; appears to be similar to risperidone
Weight gain or metabolic disorders Clear Appears to be similar to risperidone
Improves quality of life Moderate Improves ability to function in daily life; comparisons with other second-generation
antipsychotics needed
Effective in treatment-resistant schizophrenia None Evidence needed
Economic evidence
Cost effectiveness None Likely to be more expensive than generic risperidone
PANSS, Positive and Negative Symptom Scale.Scope, aims, and objectives
Paliperidone, the 9-hydroxy metabolite of risperidone, is a
second-generation antipsychotic that was approved on
December 20, 2006 by the US Food and Drug Administration
(FDA) for the treatment of schizophrenia. Risperidone is
extensively used, and has received regulatory approvals for the
treatment of schizophrenia, bipolar mania, and, more recently,
irritability associated with autistic disorder in children and
adolescents. Paliperidone (Invegaﾮ, Janssen Pharmaceuticals) is
being promoted as having a distinct treatment profile with an
innovative pharmacologic delivery system, being effective when
given once daily, able to be initiated at a potentially therapeutic
dose, and being less likely to interfere with other medications that
are metabolized by the liver. As a metabolite of risperidone,
however, it is probable that paliperidone has a similar efficacy and
side effect profile to risperidone. This is a particularly relevant
issue given the pending availability of inexpensive generic
formulations of risperidone.
The objective of this review is to assess the impact of
paliperidone on the treatment and clinical management of
schizophrenia. Specific attention is given to evidence for potential
advantages/disadvantages when compared with risperidone.
Methods
Clinical trial information was accessed by English language
searches conducted on September 5, 2007 using PubMed
(http://www.ncbi.nlm.gov/entrez) with the search terms:
“paliperidone” or “9-hydroxy-risperidone.”
Clinical trials of paliperidone and clinically relevant publications of
paliperidone pharmacokinetics, side effects, and drug–drug
interactions were included in this review. Review articles,
duplicate publications, and articles not directly related to the
clinical use of paliperidone in schizophrenia were excluded.
Posters presented at national and international meetings were
specifically excluded from our synthesis and analysis because
posters are not ordinarily subject to peer review and their content
can be subject to change prior to publication. A request was
made to Ortho-McNeil Janssen Scientific Affairs, LLC of Titusville,
NJ, USA for copies of any original research of paliperidone
already accepted for publication and still in press as of
September 29, 2007, but this did not generate any additional
publications for review. A Cochrane Collaboration review of
paliperidone is currently in progress (Nussbaum & Stroup 2007).
The evidence base included in the review is shown in Table 1.
Disease overview
Characteristics of schizophrenia
Schizophrenia is a complex condition, increasingly recognized as
a neurodevelopmental disorder. DSM IV-TR (American Psychiatric
Association 2000) criteria include having at least two of the
following five symptoms: 1) delusions, 2) hallucinations, 3) grossly
disorganized behavior, 4) catatonic behavior, or 5) negative
symptoms. Having only bizarre delusions, or hallucinations that
affect behavior, or hallucinations of conversing voices would also
meet the criteria. Additionally, symptoms must last at least six
months, be associated with marked impairment in functioning,
and not be better explained by another condition.
While the most striking symptoms of schizophrenia are the
positive symptoms (easy-to-spot behaviors not typically seen in
healthy people that usually involve a loss of contact with reality,
i.e. delusions or hallucinations), it is often the less obvious
symptoms that are more associated with poor functioning (Siegel
et al. 2006). Negative symptoms (Stahl & Buckley 2007), or
reductions in normal emotional and behavioral states, are often
associated with disability. Additionally, schizophrenia often
occurs with significant impairment in cognition (Green et al. 2000;
Keefe et al. 2006), and a substantial decline from premorbid IQ
(Reichenberg et al. 2005). Impaired performance on measures of
neurocognition is closely linked to community outcome (Green et
al. 2000). Substance abuse is common in patients with
schizophrenia, with some studies reporting up to 50%
comorbidity (Green et al. 2007), and association with more severe
symptoms and a poorer outcome.
Schizophrenia is also correlated with poor physical health,
including higher rates of obesity, diabetes, hypertension,
metabolic syndrome, and cardiovascular disease (Mitchell &
Malone 2006). This risk is multifactorial, involving shared
vulnerability, genetic factors, and unhealthy lifestyle, as well as
the potential impact of antipsychotics.
Prevalence of schizophrenia
The prevalence of schizophrenia is commonly reported as 1% of
the adult population worldwide, although some report lower
percentages (Goldner et al. 2002). Typical onset is during
adolescence, with peak ages of diagnosis of 20–28 years for men
and 26–32 years for women (Castle et al. 1991). The disease is
often subdivided into several phases (H￤fner & an der Heiden
1999): premorbid (pre-illness), prodromal (attenuated symptoms),
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Category Number of records
Initial search 131
records excluded 95
records included 36
Additional studies identified 2
Level 1 clinical evidence (systematic review,
meta analysis)
0
Level 2 clinical evidence (RCT) 5
Level ≥3 clinical evidence 31
relevant laboratory 31
studies in humans 0
Economic evidence 0
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review263
psychotic (full presence of symptoms), and residual (between
prodromal and active psychosis, with a lack of a return to
baseline). Often, patients shift between periods of active
psychotic exacerbations and residual phases.
Pathophysiology
Clear cause and effect relationships for schizophrenia are
unknown, but advances have been made recently. Since the
1960s, the dopamine hypothesis has been prominent (i.e.
schizophrenia is caused by excess dopamine in the brain), and
although this explains part of the process, the pathophysiology
is substantially more complex. Although a full survey is beyond
the scope of this review, the ultimate etiology of schizophrenia
may be related to disturbances in regulation of trophic genes
such as neuregulin or dysbindin (Norton et al. 2006),
neurochemical alterations (Boks et al. 2007), or adverse
environmental events (Byrne et al. 2007; Muller & Schwarz
2006). However, disturbances of specific neurotransmitter
systems, particularly dopamine (Di Forti et al. 2007), glutamate
(Javitt 2004), and gamma-aminobutyric acid (GABA) (Vacher et
al. 2006) may be the proximate cause of symptoms and
neurocognitive deficits.
Other, not mutually exclusive, theories include a deficit in myelin
or white matter (Davis et al. 2003), aberrant synaptic pruning
(Hoffman & McGlashan 1997), and an association with adolescent
cannabis (Moore et al. 2007). Genetic evidence is sometimes
conflicting, but several putative susceptibility genes (including
COMT, DISC1, RGS4, GRM3, and G72) have been identified
(Harrison & Weinberger 2005).
Post-mortem studies have identified localized alterations of specific
neuronal, synaptic, and glial populations in the hippocampus,
dorsolateral prefrontal cortex, and dorsal thalamus (Harrison et al.
2005). Inhibitory interneurons are particularly affected, as
demonstrated by a decrease in their number, diminished
expression of synthesizing enzyme, diminished expression of
neuropeptides, and decreased migration of neurons into the cortex
from the underlying white matter (Akbarian et al. 1996; Benes et al.
1998; Woo et al. 1998). The total number of neurons is diminished
in certain areas of the brain (Jeste & Lohr 1989), and, moreover,
magnetic resonance imaging (MRI) demonstrates corresponding
enlarged ventricles and diminished volume in the hippocampus and
the superior temporal cortex (Kubicki et al. 2002).
Epidemiology
Schizophrenia is associated with a high burden of illness, in large
part because of its onset during adolescence and the subsequent
loss of the prime working years. Only a minority of patients ever
achieve gainful employment, and less than 50% of patients in the
United States raise families (Javitt & Coyle 2004). Approximately
15% spend many years in mental health facilities, and another
15% are incarcerated for petty crimes and vagrancy; 60% live in
poverty, with a 5–15% prevalence of homelessness (Folsom et al.
2005; Javitt et al. 2004). Furthermore, 10% of patients attempt
suicide, often by violent means (Hunt et al. 2006).
Current therapy options
Antipsychotics are the mainstay of treatment for schizophrenia
and, although psychotherapy and psychosocial treatments have
an important role, this review will focus on the pharmacologic
management of schizophrenia. Although antipsychotics with
novel mechanisms of action are on the horizon (Heresco-Levy et
al. 2005; Patil et al. 2007), at present all marketed antipsychotics
share in common a blockade of the dopamine type 2 (D2) receptor
(Di Forti et al. 2007), and primarily are only effective on positive
symptoms (Lieberman et al. 2005). There is evidence that all
available antipsychotics, with the exception of clozapine and
possibly olanzapine, have approximately equivalent efficacy
(Lieberman et al. 2005; Jones et al. 2006; McEvoy et al. 2006).
Others have found advantages for clozapine, olanzapine,
amisulpride, and risperidone in a systematic review (Davis et
al. 2003).
Conventional, or first-generation, antipsychotics are primarily D2
blockers, and can be divided into three groups: high, medium,
and low potency. High potency is generally associated with a
higher rate of extrapyramidal symptoms (EPS), namely acute
dystonia, parkinsonism or akathisia; haloperidol is a
representative example. Low potency is generally associated
with higher sedation and anticholinergic side effects;
chlorpromazine is a representative example. Medium potency is
generally somewhere in between, with perphenazine a
representative example.
Atypical, or second-generation, antipsychotics bind primarily to
different degrees to both the D2 receptor and the serotonin2A
(5-HT2A) receptor. In addition, all demonstrate some antagonism
at other dopamine and serotonin receptors. All are distinguished
from the first-generation antipsychotics by a lower propensity
for causing EPS. In addition to paliperidone and risperidone,
the second-generation agents currently marketed in the
United States are clozapine, olanzapine, quetiapine, ziprasidone,
and aripiprazole.
Adverse effects are a significant issue for all antipsychotics, and
to a certain extent distinguish the various medications,
particularly the second-generation antipsychotics, from each
other. Although more common with the first-generation
antipsychotics, all have the potential to cause EPS. Tardive
dyskinesia is a disfiguring, potentially disabling, and potentially
permanent movement disorder associated with antipsychotics
that may be more common with first-generation drugs (Correll et
al. 2004), although this is debated (Jones et al. 2006; Rosenheck
2007). Second-generation antipsychotics also have a higher
propensity for weight gain, with this effect being less for
risperidone and quetiapine compared with clozapine and
olanzapine, and least frequent with aripiprazole and ziprasidone
(Citrome 2007). Other potential side effects of both first- and
second-generation antipsychotics include hyperprolactinemia,
orthostatic hypotension, blood dyscrasias, gastrointestinal
distress, and neuroleptic malignant syndrome. Often, an
individual drug’s side effect profile must be matched with the
individual patient.
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psychosocial disability costs (unemployment, disability
payments), hospitalization costs, and outpatient clinical and
social rehabilitation costs. The acquisition costs of the newer
antipsychotic medications also play a role in this large economic
burden. The cost effectiveness of the second-generation
antipsychotics has been questioned, with recent studies raising
serious doubts. The cost effectiveness component of the Clinical
Antipsychotic Trials of Intervention Effectiveness (CATIE) found
that average monthly healthcare costs were $US300–$US500
greater with the newer second-generation medications than with
perphenazine, with no significant advantage in symptom control
or quality of life (Rosenheck et al. 2006). Other studies and
systematic reviews have come to similar conclusions (Jones et al.
2006; Polsky et al. 2006).
Nevertheless, there is a need for improvement in the
pharmacologic treatment of schizophrenia. The ideal
antipsychotic would achieve rapid stabilization of positive,
negative, and cognitive symptoms in all patients with
schizophrenia. It would also not be associated with
extrapyramidal, endocrine, metabolic, or cardiovascular side
effects, and not cause weight gain or excessive sedation.
Improvements in social functioning would also be highly
desirable. Falling short of these goals, future agents should offer
clear advantages over current agents.
Development of paliperidone
Before reviewing the clinical efficacy of paliperidone and its
potential to add to our current treatment armamentarium, we will
summarize the mechanism of action and metabolism of
risperidone and paliperidone. Although a full discussion of the
pharmacology of these medications is beyond the scope of this
review, we have tried to highlight the most clinically relevant
preclinical studies, and examine some of the purported
advantages of paliperidone.
Risperidone received regulatory approval in the United States in
1993, making it the next second-generation antipsychotic to be
marketed after clozapine. It is the precursor of 9-hydroxy-
risperidone (paliperidone). As noted above, it might be more
effective than first-generation antipsychotics, and in low to
moderate doses (under 6 mg) has a favorable side effect profile
(Davis & Chen 2004). At higher doses, EPS is common and
risperidone is the second-generation antipsychotic most likely to
cause EPS (Weiden 2007). Risperidone is associated with
moderate weight gain and is the most likely second-generation
agent to elevate prolactin (Lieberman et al. 2005), although, as
explained below, paliperidone may have an even greater
propensity to cause hyperprolactinemia, a speculation supported
by the clinical data.
Other potential side effects include somnolence (Anon. 2007c)
and urinary incontinence (Kantrowitz et al. 2006). Proposed
mechanisms for this side effect include adrenergic blockade via
alfa1 receptors or blockage of pudendal reflexes via antagonism
of 5-HT2 or 5-HT3 (Vera et al. 2001).
Paliperidone, the subject of this review, has a similar
pharmacologic profile to risperidone (van Beijsterveldt et al.
1994). Like most second-generation antipsychotics, it is an
antagonist at the dopamine D2 and serotonin 5-HT2A receptors.
There is evidence that paliperidone binds to D2 receptors less
tightly (Seeman 2005), suggesting that paliperidone might cause
fewer extrapyramidal side effects, although, as seen below, this
speculation is not supported by the clinical data. Like risperidone,
paliperidone is an antagonist at alfa1 and alfa2 adrenergic
receptors and at histaminergic H1 receptors, which could lead to
weight gain, orthostatic hypotension, or sedative side effects
(Shayegan & Stahl 2004; Anon 2007a). Neither risperidone nor
paliperidone are antagonists of muscarinic receptors, predicting a
low rate of anticholinergic side effects, including cognitive
dysfunction and gastrointestinal disturbances (Shayegan & Stahl
al. 2004).
Animal studies using oral risperidone have shown that the
cerebral distribution of its metabolite paliperidone was more
limited than that of risperidone, with mean residence times in the
frontal cortex and striatum of 4–6 hours for risperidone, compared
with approximately 12 hours for paliperidone (van Beijsterveldt et
al. 1994). These mean residence times were 3–5 times longer than
those observed in plasma and in the cerebellum (van Beijsterveldt
et al. 1994), although the clinical significance of this is unclear.
Paliperidone is primarily metabolized and excreted renally (Anon.
2007a), and thus may be of particular utility for patients with mild
to moderate hepatic impairment. This is in contrast to risperidone,
which is metabolized to paliperidone by the liver. Paliperidone is
recommended to be given at lower doses in patients with
renal impairment.
A large number of studies have been performed with oral
risperidone and thus, by default, its metabolite paliperidone. No
correlation has been found between plasma levels of risperidone
or its metabolite paliperidone on antipsychotic response
measured by the Positive and Negative Symptom Scale (PANSS),
but higher concentrations in plasma were associated with
patients who developed clinically significant parkinsonian
symptoms (Spina et al. 2001). There is in-vitro evidence that oral
risperidone might inhibit the metabolism of its metabolite
paliperidone in the brain (Zhu et al. 2007), theoretically resulting in
a lower central nervous system (CNS) concentration when oral
paliperidone is used. In other words, this would predict a lower
potency for oral paliperidone, a speculation supported by the
lower end of the effective dose for paliperidone (6 mg) being
higher than the corresponding dose for risperidone (3 mg).
In contrast to risperidone, paliperidone is available in an oral
extended-release formulation, using a patented technology called
osmotic controlled-release oral delivery system (OROS) (Conley
et al. 2006). The extended-release formulation of paliperidone
consists of an osmotically active trilayer core, composed of two
drug layers and a push layer (Conley et al. 2006), and can be
administered once daily. It is thought that by reducing the
amplitude of the peaks and troughs, which are seen with
immediate-release oral therapies in general, the risk of adverse
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effects may be reduced. This speculation has not been tested in
a head-to-head comparison with risperidone and, as seen below,
is not well supported by the clinical data.
Although of unclear clinical significance, past studies of
risperidone and its metabolite concentrations reported that the
serum concentration of paliperidone can differ with both the
formulation used and the age of the patient. The paliperidone to
risperidone ratio has been found to be comparatively lower in
patients receiving the long-acting injectable formulation of
risperidone than in those receiving oral risperidone (Nesv￥g et al.
2006), a potential consideration when switching from paliperidone
to long-acting injectable risperidone. After controlling for dose,
higher serum concentrations are seen in patients older than
42 years, but there are no significant sex-related differences in the
average plasma concentrations (Aichhorn et al. 2005b). In
addition, the paliperidone to risperidone ratio can be highly
variable, with some patients receiving risperidone having
risperidone plasma levels that were nondetectable and relatively
high plasma levels of paliperidone (Aravagiri et al. 2003). Similar
to other second-generation agents (Eberhard-Gran et al. 2006),
paliperidone is detectable in breast milk (Aichhorn et al. 2005a).
Several potential drug–drug interactions have been reported for
oral risperidone. Antidepressants, such as paroxetine (Saito et al.
2005), sertraline (Spina et al. 2004), and fluoxetine (Bondolfi et al.
2002), can increase the concentration of risperidone and its
metabolite paliperidone, but this is not the case for valproic acid
(Ravindran et al. 2004; Yoshimura et al. 2007), topirimate (Migliardi
et al. 2007), lamotrigine (Spina et al. 2006), mirtazapine (Loonen
et al. 1999), and venlafaxine (Amchin et al. 1999). Carbamazapine
can decrease the concentration of the metabolite paliperidone in
patients receiving risperidone (Spina et al. 2000). The clinical
significance of these observations with oral risperidone is
unknown, and it is likely that many will not be relevant with orally
prescribed paliperidone because of its minimal hepatic
metabolism—a potential advantage for paliperidone.
Clinical evidence with paliperidone
Efficacy
As of September 5, 2007, 27 clinical trials of paliperidone were
listed on www.clinicaltrials.gov, a repository operated by the US
National Institutes of Health and the National Library of Medicine.
Of these, 20 were primarily in patients with schizophrenia.
At the time of writing, three efficacy trials of paliperidone have been
published (Davidson et al. 2007; Kane et al. 2007; Marder et al.
2007). All three were similar 6-week, randomized, placebo-
controlled trials in patients with schizophrenia, with an additional
active comparator arm (olanzapine 10 mg). On the basis of these
three trials, paliperidone 6 mg to 12 mg daily was approved for the
treatment of acute schizophrenia. The three trials are summarized
in Table 2. Response rates and adverse events to the various
dosages across the three trials have been combined, except for
EPS, for which the package inserts were used. To aid clarity, results
for the nonefficacious dose of paliperidone 3 mg are not included.
Using similar designs and inclusion criteria, these three studies
tested the efficacy and safety of paliperidone extended-release
over a 6-week period by comparing fixed doses of 3 mg, 6 mg,
9 mg, 12 mg, and 15 mg administered once daily versus placebo.
Not all doses were tested in every study, but olanzapine 10 mg
administered once daily was used as an active control in all three
trials. The primary efficacy outcome measure was change in
PANSS total score from baseline to endpoint.
In total, 1555 patients with an acute episode of schizophrenia
were randomized at multiple sites worldwide. The patients’ mean
ages ranged from 36.8 to 41.6 years, and they were generally
male and Caucasian. The mean age at diagnosis was 25 to 27
years and between 25% and 42% had been hospitalized at least
four times (specific proportions varied in the three studies). Mean
baseline PANSS score was approximately 94.
As seen in Table 2, paliperidone is efficacious, and begins to
separate from placebo as early as day 4. It clearly performs better
than placebo, and while these studies were not powered to
directly compare with olanzapine, it appears that they are at least
as efficacious as a starting dose of olanzapine. There is evidence
that the near maximal effective dose of olanzapine is >16 mg
(Davis et al. 2004). A comparison with a more typical therapeutic
dose of olanzapine, as well as with risperidone, would be useful
to assess differential response.
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Treatment and
dose
Placebo Paliperidone Olanzapine
6 mg 9 mg 12 mg 15 mg
Number of
patients
356 235 245 242 113 364
Completion rate
after 6 weeks
(%)
39.4 55.7 66.6 64 71.3 62.4
Response rate
(%)a
26.6 53.2 48.6 56.7 53 50.5
NNT for
response vs
placebo
NA 3 4 3 3 4
EPS (%) NA 10.2 25.2 26 Not
reported
25
Somnolence
(%)
7 8.5 9.8 4 8.8 16.4
Insomnia
(%)
14.6 12.8 15.5 6.6 15.9 11.8
All data, except EPS, are pooled from the three efficacy trials of paliperidone. Data to pool
EPS data were not reported, necessitating use of the paliperdone and olanzapine package
inserts, which do not report data for placebo or the unapproved 15 mg dose.
aResponse rate is improvement by 30% on the PANSS.
EPS, extrapyramidal symptoms; NNT, number needed to treat, calculated as the reciprocal
of the difference in response rates for medication vs placebo; PANSS, Positive and
Negative Symptom Scale.
Table 2 | Summary of the efficacy of paliperidone 6 to
15 mg/day in patients with schizophrenia (Anon.
2007a; Davidson et al. 2007; Kane et al. 2007;
Marder et al. 2007)As noted above, paliperidone is approved at a daily dosage of
6 mg to 12 mg, and although the manufacturer states that the
starting dose of 6 mg is generally therapeutic, this may not be
appropriate for all patients. Response rates appear to be
generally equivalent, with the highest rate of 56.7% achieved
with the 12 mg dose, the 6 mg and 15 mg being nearly identical
at 53%, and the lowest rate of 48.6% with 9 mg. The completion
rates (confidence intervals in parentheses), however, which
range from 55.7% (0.4935–0.6195) at 6 mg, 66.6% (0.6040–
0.7215) at 9mg, 64% (0.5782–0.6984) at 12 mg, and 71.3%
(0.6274–0.7920) at 15 mg, appear to show an increased
likelihood for patients assigned to the higher doses to complete
the trial, although the modified Wald confidence intervals
overlap. It should be noted that the 15 mg data are based only
on one trial (Davidson et al. 2007). The tendency to have greater
completion rates with larger doses despite an increased
likelihood of side effects in higher doses (see below), combined
with a tendency for psychiatrists to prescribe doses greater than
6 mg in flexible dose trials (see below), can be interpreted as
evidence for a dose response, although alternative
interpretations are possible since completion rates represent the
proportion of patients who have not dropped out for whatever
reason (e.g. lack of efficacy, withdrawal of consent, adverse
effects). As seen in the table, the number needed to treat
appears to be equivalent between the dosages. Longer follow-
up trials are needed to determine whether the majority of
patients will have their symptoms sufficiently controlled
by 6 mg.
The mean decreases in PANSS total scores range from 2.9 to 8
for placebo, and 15.7 to 17.9, 16.3 to 17.2, 17.5 to 23.3, and 19.9
for paliperidone 6 mg, 9 mg, 12 mg and 15 mg, respectively, and
18.1 to 19.9 for olanzapine. Paliperidone showed statistically
significant improvements over placebo at all doses tested. This
was also the case for the PANSS scores examining positive
symptoms, negative symptoms, depression/anxiety, uncontrolled
hostility/excitement, and disorganization.
Improvements in personal and social functioning, assessed using
the single item Personal and Social Performance Scale (PSP)
(Morosini et al. 2000), were greater for paliperidone compared
with placebo. Based on these findings, paliperidone is the only
antipsychotic that can be marketed as improving social
functioning. This claim of uniqueness, however, is tempered by a
comparable improvement found in the starting dose olanzapine
group, and the CATIE report of significant within-group
improvements in overall quality of life for olanzapine and
risperidone, and no between group differences between
antipsychotics (Swartz et al. 2007).
Safety and tolerability
The completion rates indicate good tolerability for paliperidone,
although direct comparisons with risperidone are not available.
Of note, while the initial efficacy trials report short-term
completion rates for the 6 mg dose of risperidone of >70%
(Chouinard et al. 1993), the 18-month CATIE trial offers a more
pessimistic 26%.
Tachycardia was the most common adverse event and led to a
2% discontinuation rate for the 12 mg dose in one of the trials
(Kane et al. 2007). Tachycardia occurred in 7% of those
randomized to placebo, 12%, 12%, and 14% of those
randomized to paliperidone 6 mg, 9 mg, and 12 mg, respectively,
and 9% of those randomized to olanzapine. Tachycardia is not
commonly associated with risperidone: it is reported at 2% at
commonly accepted dose ranges (Anon. 2007c). A prolonged QTc
interval was noted with paliperidone in 3% to 5% of patients
among the three trials (Anon. 2007a), although this is unlikely to
be clinically important unless the drug is used in the presence of
other risk factors for QTc prolongation.
Despite speculation that the extended-release formulation would
lead to a reduced risk of adverse effects, paliperidone appears to
cause a somewhat higher rate of parkinsonism and EPS than
risperidone, especially at dosages of 9 mg and 12 mg (Anon.
2007a). The rates reported for paliperidone 6 mg (10.2%) appear
to be slightly lower than for usually therapeutic dosages of
risperidone (Anon. 2007c), in which EPS rates of 11% and 17%
were reported for 4 mg and 6 mg, respectively.
Although the data necessary for pooling were not reported,
statistically higher scores were seen on the Barnes Akathisia
Rating Scale and the Simpson–Angus Rating Scale for
paliperidone 9 mg and 12 mg compared with placebo in one
trial (Kane et al. 2007); on the Barnes Akathisia Rating Scale for
paliperidone 6 mg in the second trial (Marder et al. 2007); and for
the 9 mg dose in the Simpson–Angus Rating Scale in the third
(Davidson et al. 2007).
As noted earlier, risperidone has the highest propensity of all the
second-generation agents to cause hyperprolactinemia, with the
potential to cause oligomenorrhea or amenorrhea in women,
erectile dysfunction in men, and loss of libido and infertility in both
sexes (Molitch 2005) and potentially osteoporosis (Howes et al.
2005). There is evidence that prolactin elevation is more closely
related to paliperidone concentration, rather than risperidone
concentration (Knegtering et al. 2005; Melkersson 2006). This
could lead to higher prolactin elevations with paliperidone than
with risperidone.
In the three short-term trials, paliperidone appears to lead to a
dose-dependent elevation in prolactin, although symptomatic
hyperprolactemia (including galactorrhea, gynecomastia,
amenorrhea, anorgasmia, and abnormal sexual function) was low
(eight patients overall). Data necessary to pool data and evaluate
the likelihood of developing hyperprolactinemia were not
reported. Larger increases were noted in females, and
minimal increases, if any, were noted in the olanzapine and
placebo groups.
Across the individual efficacy trials, the mean increases in
prolactin from baseline for men were 15.4 ng/mL for 3 mg
(Davidson et al. 2007), 22.8 ng/mL for 6 mg (Marder et al. 2007),
29.2 ng/mL for 9 mg (Davidson et al. 2007), 24.3 ng/mL for 12 mg
(Marder et al. 2007) and 35.2 ng/mL for 15 mg (Davidson et al.
2007). For women, the mean increases were 62 ng/mL for
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3 mg (Davidson et al. 2007), 81.1 ng/mL for 6 mg (Marder et al.
2007), 79.9 ng/mL for 9 mg (Davidson et al. 2007), 76.4 ng/mL for
12 mg (Marder et al. 2007) and 106.9 ng/mL for 15 mg (Davidson
et al. 2007). In the study by Kane et al. (2007), only the across-
dose mean is presented: 27.9 ng/mL for men and 86 ng/mL
for women.
Although it was a longer trial, the CATIE study (Lieberman et al.
2005) reported smaller cross-gender mean increases (15.4 ng/dL)
in patients treated with a moderate dose of risperidone (mean
3.9 mg). Another recent publication (Potkin et al. 2006) reported a
cross-gender mean increase of 18 ng/mL. Longer follow-up for
treatment-emergent prolactin-related adverse events is needed,
but the clinical data thus far support the preclinical evidence for a
greater prolactin increase with paliperidone than risperidone.
Only a few glucose-related adverse events were seen in trials with
paliperidone, and minimal changes were noted in metabolic
parameters. The percent of patients with a gain of ≥7% of
bodyweight was similar for the paliperidone 3 mg and 6 mg (7%
and 6%, respectively) and placebo (5%) groups, but there was a
higher incidence of weight gain at higher doses. Specifically, rates
for the 9 mg, 12 mg, and 15 mg dosages were 9%, 9%, and 18%,
respectively. In contrast, 17.5% of patients on olanzapine
experienced ≥7% weight gain. There were no clinically relevant
changes in mean fasting serum glucose, insulin or serum lipid
levels (low density lipoprotein, high density lipoprotein, and
triglycerides) or in renal function. This is consistent with
risperidone’s metabolic profile, although the incidence of ≥7%
weight gain is comparatively lower than that reported for
commonly prescribed doses of risperidone (18%) (Anon. 2007c).
Insomnia and somnolence
In the three efficacy trials, rates of somnolence and insomnia were
4% to 9.8%, and 12.8% to 15.9%, respectively, for the various
doses of paliperidone. As seen in Table 2, there is evidence for a
U-shaped dose response for paliperidone in treating sleep
disorders, with rates decreasing with escalating doses until
12 mg, and then increasing rates of sleep-related adverse events
at 15 mg. This finding is notable because of the increasing
understanding of the intrinsic connections between subjective
and objective sleep deficits in schizophrenia. For example, in the
CATIE study, residual insomnia occurred in 16–30% of patients
across treatment arms (Lieberman et al. 2005), and has been
related to reduced quality of life and poor coping skills (Ritsner et
al. 2004; Hofstetter et al. 2005). Objective polysomnographic
measurements of sleep have been correlated with PANSS scores
(Yang & Winkelman 2006) and various neurocognitive tests (G￶der
et al. 2004). It is possible, although speculative, that a correction
of subjective and objective sleep deficits in schizophrenia would
lead to clinical improvement.
The objective and subjective effects of paliperidone on sleep in
schizophrenia were tested in a 2-week double-blind study
(Luthringer et al. 2007). In this study, 36 patients with stable
schizophrenia and insomnia related to schizophrenia underwent a
2-week antipsychotic taper and then were randomized to 2 weeks
of paliperidone 9 mg or placebo. Patients were given the Leeds
Sleep Evaluation Questionnaire (LSEQ) (Parrott & Hindmarch
1980) and underwent polysomnographic evaluations at the
beginning and the end of the study. Although the groups were
randomized, it is unclear if there were any significant baseline
differences between the two groups in sleep architecture
variables, as the paper makes no claim about the statistical
similarity at baseline, although it does state that they were
“generally well matched.” The study reports several significant
changes between baseline and endpoint in the paliperidone
group compared with the changes observed in the placebo
group. Most notable were improvements in total sleep, sleep
continuity, and in stage II sleep, although these results are limited
by the misleading setting of alfa at the 0.1 level in the paper. It also
should be noted that paliperidone was associated with decreased
slow-wave sleep, although this was not statistically significant.
This study is commendable as data on the long-term effects of
antipsychotics on sleep architecture are scarce. In a shorter
study, risperidone has also been associated with improved
subjective sleep (Dursun et al. 1999).
Prevention of recurrence
The effectiveness of paliperidone in preventing relapse was
tested in a three-phase trial (Kramer et al. 2007). The
methodology of this study is similar to other relapse prevention
studies with other psychotropic drugs. A total of 530 patients
with a baseline PANSS score of 70–120 and no documented
treatment failure with risperidone were enrolled and began
phase 1, an 8-week open-label run-in phase where they
received a starting daily dose of paliperidone 9 mg, with
increases/decreases of 3 mg per week to a maximum
allowable dose of 15 mg daily. Phase 2 followed; a
6-week stabilization phase where the dose established in the
run-in phase was continued. Response criteria necessary to
enter phase 2 were not specified, other than patients being
deemed stable for 2 weeks. The modal daily dose in phase 2 was
9 mg (45%), with 47% of patients needing increases to doses of
12–15 mg, and only 8% controlled by doses of 6 mg or less.
In the trial, 312 patients entered phase 2, and 207 patients
subsequently entered phase 3, a double-blind phase where they
were randomized to receive placebo or paliperidone at the dose
they were receiving in the stabilization phase. Again, response
criteria for patients to be eligible to enter the double-blind phase
were not specified. During the double-blind treatment phase, the
most frequently reported adverse effects were insomnia (5% for
paliperidone, 6% for placebo), tachycardia (15% paliperidone,
8% placebo), and orthostatic hypotension (5% paliperidone, 2%
placebo). Extrapyramidal symptoms were observed in 7% of
patients taking paliperidone (compared with 3% taking placebo).
Similar to the efficacy trials, prolactin levels were increased in
patients taking paliperidone compared with placebo, with a 4%
incidence of prolactin-related adverse events (e.g. breast
enlargement in men, amenorrhea, and galactorrhea). Overall, the
mean weight gain was 1.8 kg for paliperidone and 0.2 kg for
placebo, with no significant changes in serum insulin, glucose, or
lipids. It should be noted that these reports are only for the
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paliperidone through the first two phases, and that reports of
adverse events were considerably higher in the first two phases.
The duration of the double-blind phase was variable, and would
continue until the patient experienced a recurrence (defined as
hospitalization, specified increase in PANSS, specified dangerous
behavior, or specified worsening on the Clinical Global
Impressions—Severity of Illness scale), or until study termination.
Details about the conversion to placebo, including rapidity of
conversion, were not reported. A planned interim analysis was
performed after 43 recurrence events, and the study was
terminated early on the basis of significant efficacy results, which
showed that 25% of the placebo group experienced a predefined
recurrence at 23 days, versus 68 days in the paliperidone group
(P<0.001). Overall, recurrence occurred in 52% and 22% of the
placebo and paliperidone groups, respectively (NNT 4).
Several methodologic issues of this study bear further discussion.
Firstly, 323 patients were not randomized to the double-blind
stage (phase 3). Furthermore, 91 of these patients had not
completed phase 1 or 2 when the study was prematurely
stopped, so the total number of dropouts was 232 (52%). Listed
reasons for dropouts are vague. For immediately before and
during phase 2, 124 subjects (53%) dropped out because of
“criteria not met” or “subject choice.” An additional 33 subjects
(14%) were lost to follow-up. Moreover, the majority of the
dropouts in the double-blind phase were for similar reasons.
Dropouts are not considered recurrences, but all of the listed
reasons could potentially be referring to treatment failure,
especially given the lack of detail reported of the response criteria
necessary to proceed to the next phase. Second, the rapidity of
conversion to placebo is not reported, and it is possible that the
results are more descriptive of the rate of recurrence with
antipsychotic withdrawal. An active comparator arm would have
been informative. Third, the large majority of patients (92%)
required a paliperidone dose greater than 6 mg to control their
symptoms. Although the starting dose of 9 mg is a potential
confounding variable, this is evidence against the starting dose of
6 mg being therapeutic for the majority of patients.
A more conservative conclusion to this study is that patients
responsive to, and able to tolerate, paliperidone are more likely to
have a recurrence when their paliperidone is stopped in
comparison to continued treatment. Of note is the evidence that
risperidone has been shown to be effective in maintenance
treatment of schizophrenia, equivalent to haloperidol in one study
(Marder et al. 2003), and superior in another (Csernansky &
Schuchart 2002; Marder et al. 2003).
Economic evidence and resource utilization
As noted above, the economic burden of schizophrenia is large
for many reasons, only partly because of the acquisition costs of
brand name medications. No formal economic analysis has been
published for paliperidone. However, the costs of paliperidone
and risperidone are likely to be substantially different when
risperidone is no longer governed by patent protection in June
2008. At the time of writing, the cost of a paliperidone 3 mg or
6 mg tablet is $US9.54, and that for a 9 mg tablet is $US14.31
(Rockland Psychiatric Center Pharmacy, Orangeburg, NY, USA,
October 1, 2007). Risperidone 4 mg, meanwhile, costs $US9.75
(ibid). In Canada, however, where risperidone has been available
as a generic medication since July 2006, the generic 4 mg tablet
is now available for 43% of the cost of branded risperidone, at
$Can1.92 compared with $Can4.40 for the branded product
(Anon. 2007b).
Assuming that both the price of paliperidone 6 mg will remain
constant and that generic and branded risperidone will have an
equivalent price ratio in the United States as it does in Canada,
using generic risperidone 4 mg over paliperidone 6 mg would lead
to an annual saving of approximately $US2000 per patient.
However, potential savings in hospital costs could make up this
difference if paliperidone leads to a quicker response or improved
social functioning. Significant separation from placebo is seen as
early as day 4 in the three efficacy trials, although a similar
analysis of data was not done for olanzapine. Moreover, the long-
term relapse prevention trial in which titration of medication was
allowable resulted in mean doses of paliperidone greater than 6
mg. While paliperidone did improve functioning on the PSP,
similar results are reported for olanzapine and risperidone in the
three efficacy trials and CATIE trial, respectively.
To repeat, a direct comparison with other antipsychotics is
needed before definitive recommendations about these potential
benefits can be made. It can, however, be said with confidence
that paliperidone is likely to cost considerably more than generic
risperidone. A trial of economic outcomes for patients treated
with paliperidone is currently recruiting patients, as listed at
www.clinicaltrials.gov/ct2/show/NCT00488891?term=paliperidon
e&rank=32.
Patient group/population
Paliperidone is effective compared with placebo in the acute
treatment of schizophrenia in adults. The once-a-day dosing is
helpful. Given its lack of hepatic metabolism, it may be
particularly useful in patients with liver disease. No trials have
been performed in other disease classifications, in contrast to
risperidone, which has regulatory approval to treat bipolar mania
and irritability associated with autistic disorder in children and
adolescents. Several ongoing/planned trials for paliperidone in
other diagnostic groups are listed on www.clinicaltrials.gov.
Dosage, administration, and formulations
Paliperidone (Invega) is available as 3, 6, and 9 mg tablets. At
present, only the extended-release oral formulation is available.
The recommended starting dose is 6 mg once daily, administered
in the morning. Initial dose titration is not recommended in the
product labeling, which also recommends that dose increases
generally should occur at intervals of more than 5 days in
increments of 3 mg/day if considered necessary. The maximum
recommended dose is 12 mg/day. For patients with mild renal
impairment (creatinine clearance ≥50 to <80 mL/min), the
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maximum recommended dose is 6 mg/day. For patients with
moderate to severe renal impairment (creatinine clearance 10 to
<50 mL/min), the maximum recommended dose is 3 mg/day.
Paliperidone must be swallowed whole and should not be
chewed, divided, or crushed. The tablet shell, along with insoluble
core components, is eliminated from the body in the stool.
Place in therapy
Schizophrenia is a severe, chronic, and disabling illness. Although
many different antipsychotic drugs are available, their overall
effectiveness is less than optimal. Some patients have no
response to available drugs. Other patients have residual
symptoms despite adequate drug treatment. Many patients
respond to treatment, but have noxious or intolerable side effects
that often contribute to poor medication adherence. For these
reasons, new drug therapies are always needed, and the purpose
of this review was to evaluate the place of paliperidone in the
treatment of schizophrenia.
Paliperidone has a significantly different hepatic enzyme and
metabolic profile compared with risperidone and several other
atypical antipsychotic drugs, and is more effective than placebo
in treating schizophrenia. It appears to be equivalent in efficacy to
a relatively low dose of olanzapine. It remains to be seen whether
it should be used in place of risperidone; the only clear advantage
of paliperidone is the minimal hepatic metabolism, which may be
important with respect to drug interaction potential. Although the
extended-release formulation allows for once-daily
administration, risperidone is also approved for this dosage
frequency. A claim that paliperidone can be initiated at a
therapeutic dose and has unique benefits in improving social
functioning is only minimally supported by the limited evidence
currently available (Kramer et al. 2007). Additionally, there is
preliminary evidence that paliperidone may lead to greater EPS
(at doses greater than 6 mg/day) and prolactin elevations
than risperidone.
A controlled clinical trial directly comparing paliperidone and
risperidone is highly desirable in order to contrast and compare
these two agents. Until such a trial is performed, despite its
effectiveness over placebo and theoretical advantages, it is
difficult to justify first-line paliperidone use over risperidone, and
it will become even harder to justify when risperidone becomes
available as a less expensive generic medication.
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